Analyst Ratings for Royalty Pharma (RPRX) [Buys]
RPRX Rating Summary
RPRX Price Target Summary
- Highest: $50.00 (Goldman Sachs)
- Lowest: $38.00 (BofA Securities)
- Average: $43.40
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$43.40 (+54.2%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 80%
Rating Score: 7.5 / 10
Percentile Rank: 80%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/14/2022 | UBS » Updated 8/9/2023 |
Ashwani Verma | New Coverage | Buy (N/A) |
41.00 (44.00) |
40.48 (28.15) |
-30.46% | Details |
| 5/13/2022 | Scotiabank | Adam Buckham | New Coverage | Sector Outperform (N/A) |
53.00 (N/A) |
38.95 (28.15) |
-27.73% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
